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Abstract 
Low serum bilirubin levels are associated with the risk of cardiovascular diseases 
including peripheral artery disease. Bilirubin is known to exert its property such as 
anti-oxidant effect or the enhancement of flow-mediated vasodilation, however, 
bilirubin action on angiogenesis remains unclear. To investigate the molecular 
mechanism of bilirubin on angiogenic effect, we first employed C57BL/6J mice with 
unilateral hindlimb ischemia surgery and divided the mice into two groups (vehicle-
treated group and bilirubin treated group). The analysis of laser speckle blood flow 
demonstrated the enhancement of blood flow recovery in response to ischemia of 
mice with bilirubin treatment. The density of capillaries was significantly higher in 
ischemic adductor muscles of bilirubin-treated mice. The phosphorylated levels of 
endothelial nitric oxide synthesis (eNOS) and Akt were increased in ischemic skeletal 
muscles of mice with bilirubin treatment compared vehicle treatment. In in vitro 
experiments by using human aortic endothelial cells, bilirubin augmented eNOS and 
Akt phosphorylation, cell proliferation, cell migration and tube formation. These 
bilirubin actions on endothelial cell activation were inhibited by LY294002, a 
phosphatidylinositol 3-kinase inhibitor. In conclusion, bilirubin promotes 
angiogenesis through endothelial cells activation via Akt-eNOS-dependent manner. 
Keywords: Bilirubin, angiogenesis, endothelial cells, eNOS 
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Introduction 
 Bilirubin is a metabolic end product following heme degradation.  
Hyperbilirubinemia has an aspect of cytotoxic action to cause bilirubin-induced 
neurological dysfunction in newborn (1). On the other hand, people with mild 
unconjugated nonhemolytic hyperbilirubinemia, called as Gilbert syndrome (2), have 
shown to be low prevalence of cardiovascular disease such as ischemic heart disease 
(3).  Moreover, many studies have shown that serum bilirubin levels are inversely 
associated with the incidence of coronary heart diseases (4, 5), carotid plaque and 
intima-media thickness (6, 7), and stroke (8-10) even in patients without Gilbert’s 
syndrome. Low concentration of bilirubin exerts anti-oxidant property (11), and the 
oxidative stress is actually lower in patients with Gilbert’s syndrome than those 
without Gilbert’s syndrome (12). Therefore, the potent protective mechanism of 
bilirubin on cardiovascular diseases is considered as its anti-oxidant property. 
 Increased serum bilirubin is an independent factor to reduce the prevalence 
of peripheral artery disease (PAD) (13). Angiogenesis plays an crucial role in the 
collatreal blood formation ischemia in response to insufficient peripheral circulation 
(14), and the augmentation of angiogenesis is an important therapeutic strategy for 
PAD. endothelial nitric oxide synthase (eNOS) has been shown to be a main regulator 
for angiogenesis through endothelial cells activation in both in vivo (14-16) and in 
vitro (17, 18).  Bilirubin action on endothelial function has been also elucidated. High 
serum bilirubin preserves coronary flow reserve in healthy subjects (19). Endothelium 
dependent-flow-mediated vasodilation is higher in healthy subjects with high bilirubin 
(7) and Gilbert’s syndrome (12). Thus, bilirubin is suggested to participate in 
endothelial function, however, the mechanism by which bilirubin exerts direct action 
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on endothelial cells has been still unclear 
 In the present study, we examined the molecular mechanisms of bilirubin 
action on endothelial function by using endothelial cells and mice ischemic hindlimb 
model. Bilirubin promoted vascular endothelial cells activation and angiogenesis in 
response to ischemia through Akt-eNOS-dependent manner. 
 
Methods 
Materials 
Bilirubin was purchased from Wako Pure Chemical Industries, Ltd.  (Osaka, Japan). 
The following commercially available antibodies were used in this study: anti-
phospho-Akt (Ser473), anti-total Akt, anti-phospho-eNOS (Ser1177), anti-phospho-
AMPKα  (Thr172), and anti-total AMPKα from Cell Signaling Technology (Beverly, 
MA, USA); anti-total eNOS from Santa Cruz Biotechnology (Santa Cruz, CA USA); 
anti-α-tubulin, as a loading control, from Calbiochem (San Diego, CA, USA); anti-
CD31 (PECAM-1) from Becton, Dickinson and Company (BD; Tokyo, Japan); and 
anti-α smooth muscle actin (αSMA) from Sigma-Aldrich (St. Louis, MO, USA). 
LY294002, a phosphatidylinositol 3-kinase (PI3-kinase) inhibitor was purchased from 
Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Matrigel was obtained from BD 
Biosciences Japan (Tokyo, Japan). The CellTiter 96 AQueous nonradioactive cell 
proliferation assay kit ([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium] (MTS) reagent) was purchased from Promega KK 
(Tokyo, Japan). Tempol, a free radical scavenger, was purchased from Sigma-
Aldrich. 
Murine model of ischemic hindlimb 
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All experimental procedures for mice were performed in accordance with the 
guidelines of the Animal Research Committee, University of Tokushima Graduate 
School. Eight-week-old C57/BL6J mice were obtained from Nippon CLEA (Tokyo, 
Japan) and divided into 2 groups: Bilirubin (5 mg⋅kg
-1
⋅d
-1
)-treated group and a 
vehicle-treated group. Mice were injected intraperitoneally with either Bilirubin or 
vehicle 2 d before the surgery to induce ischemic hindlimb as previously described 
(20). In brief, mice were anesthetized with intraperitoneal pentobarbital (50 mg⋅kg
-1
) 
injection and subjected to unilateral hindlimb surgery. After ligation of the proximal 
and distal ends of the left femoral artery and vein, the entire artery and vein with side 
branches were excised. 
 
Evaluation of peripheral blood flow 
The blood flow in hindlimb was measured before and immediately following surgery, 
on postoperative days 3, 7, 14, and 28 by using a laser speckle blood flow (LSBF) 
analyzing system (Omega Zone, Omega Wave Co., Tokyo, Japan), as previously 
described (20).  
 
Blood pressure measurement 
Mice blood pressure was measured by the tail-cuff method as previously described 
(20). 
 
Capillary density and Arterioles number  
Capillary density was estimated by CD31 immunohistochemistry (20, 21). Briefly, 28 
d after surgery, adductor muscles were snap frozen in liquid nitrogen-cold isopentane 
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containing optimal cutting temperature compound and cut into 8 µm cryosections. 
Capillary density was expressed as the number of CD31-positive cells corrected for 
the number of muscle fibers. Arterioles number was also evaluated by αSMA 
immunofluorescence staining. Quantification of arterioles was expressed as the 
number of αSMA-positive cells/mm
2
 of muscle area as described previously (20). 
 
Plasma bilirubin concentration measurement 
We used QuantiChrom
TM
 Bilirubin Assay Kit (BioAssay Systems, Hayward, CA) 
according to the manufacturer’s instructions to determine plasma bilirubin 
concentration. 
 
Cell culture 
Human aortic endothelial cells (HAECs) were purchased from Takara Bio Inc. (Otsu, 
Japan) and cultured in Endothelial Cell Growth Medium MV 2 (Heidelberg, 
Germany), according to the manufacturer’s protocol. HAECs during 5-8 times 
passage were used in each experiment. Cells were treated with Bilirubin dissolved in 
sterilized water. In some experiments, cells were pretreated with LY294002 (2 µM), 
tempol (100µM) or vehicle alone for 1h before bilirubin treatment.  
 
Tube-like formation assay 
Tube-like formation assay was performed by using growth factor-reduced Matrigel 
(BD Biosciences, San Jose, CA, USA), as described previously (20, 21). Briefly, 1 × 
10
4
 HAECs were cultured per well of Matrigel-coated 96-well plate in the presence of 
each concentration of bilirubin or vehicle, with or without 2 µM LY294002. Cells 
were then incubated at 37°C for 18 h. The formation of tube-like structures were 
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observed using an inverted contrast microscope and captured with a CCD camera. 
The length of tube formation was measured using the Image J 1.42 software. 
 
Scratch assay 
Cell migration was evaluated using in vitro scratch assay (22).  In brief, HAECs were 
seeded in 12-well plate and cultured at confluent monolayer. Cells were scratched and 
created in a straight line by using a p200 pipet tip. Wells were washed with culture 
medium to remove stripped cells, photographed at 0 h point, and then incubated in 
serum- and growth factor-free medium with bilirubin or vehicle for 8 h. Some 
experiments were pretreated with or without LY294002 1 h before.  Images at 8 h 
were acquired at same reference point. Migrated area was measured by Image J 1.42 
and calculated by subtracting the total area of the scratch at 8 h from the total area of 
the scratch at 0 h. 
 
Cell proliferation assay 
HAECs were seeded in 96-well plate at 1 × 10
4 
cells pre well and incubated for 24 h. 
Subsequently, various concentration of Bilirubin was added for 8 h and then cell 
proliferation was assessed 1 h after the addition of MTS reagent by measuring 
absorbance at 490 nm with a plate reader. 
Serum and growth factors deprivation-induced cell death assay 
HAECs were seeded in 96-well plates at 1 × 10
4
cells per well and cultured for 24 h. 
Then, cells were incubated in serum- and growth factor-contained medium as control 
or in serum- and growth factor-free medium with bilirubin or vehicle for 48 h, with or 
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without LY294002 pretreatment 1 h before. Serum deprivation-induced cell death was 
assessed by an MTS-based assay (21). 
Western blot analysis 
The methods protein extraction and western blot have been described in detail (20). 
Immunoblotting bands were visualized using a chemiluminescence reagent, and 
exposed to X-ray film or scanned by C-DiGit chemiluminescent scanner (LI-COR C-
DiGit Blot Scanner, Lincoln, Nebraska USA). Image J 1.42 software was used for 
densitometric analysis. 
 
Statistical analysis 
Data have been expressed as mean ± standard error of mean (SEM) values. An 
unpaired 2-tailed Student’s t-test was used to evaluate the differences between 2 
groups. For comparisons among more than 2 groups, statistical significance was 
assessed using a one-way analysis of variance (ANOVA), and the significance of each 
difference was determined by post hoc testing using Tukey-Kramer’s method. P 
values of <0.05 were considered to indicate statistical significance. 
 
Results 
Bilirubin action on in vivo angiogenesis in response to ischemia 
To evaluate bilirubin action on angiogenesis in vivo, we used a mouse model with 
unilateral hindlimb ischemia.  There were no differences in body weight, systolic 
blood pressure, or pulse rate between mice with or without bilirubin treatment at 1 
week after the surgery (Table 1). With respect to total plasma bilirubin 
concentration after an intraperitoneal injection of bilirubin, the bilirubin 
concentration was increased 2-fold at 1 h. This elevation was not significant and 
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the concentration was restored to the level in vehicle-treated mice at 6 and 24 h 
after injection (Table2).  In LSBF analyses, mice treated with bilirubin treatment 
showed that the blood flow recovery after hindlimb ischemia was accelerated 
compared to mice treated with vehicle. The LSBF ratio of ischemic side to non-
ischemic side was markedly higher at 3 d or later after ischemic hindlimb surgery in 
bilirubin-treated mice that in vehicle-treated mice (Figure 1A).   
Increased capillary density and arterioles in ischemic adductor muscle of bilirubin-
treated mice 
To evaluate proangiogenic response following induction of hindlimb ischemia, CD31- 
and αSMA-positive cells were identified in histological sections of non-ischemic- and 
ischemic-adductor muscles.  In accordance with the result of LSBF ratio, capillary 
density and arterioles number were higher in bilirubin-treated mice than in vehicle-
treated mice on day 28 after surgery (Figure 1B and C).   
In vivo bilirubin action on eNOS and Akt phosphorylation in ischemic hindlimb 
eNOS activation plays a crucial role for angiogenesis in endothelial cells (14). PI3-
kinase-Akt pathway is also shown as a key signaling for of eNOS activation (23, 24). 
Therefore, we examined whether bilirubin augmented the phosphorylation levels of 
eNOS and Akt in ischemic skeletal muscle tissue. As shown in figure 1D, eNOS 
phosphorylation, as well as Akt phosphorylation, were significantly increased in mice 
with bilirubin treatment on postoperative day 7.  These results indicate that Akt-eNOS 
signaling pathway is involved in in vivo bilirubin effects on angiogenesis. 
Bilirubin treatment suppresses superoxide production after ischemic stress 
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We analyzed the effect of bilirubin on oxidative stress by using DHE staining for 
superoxide detection, because bilirubin exerts anti-oxidant property (11). Superoxide 
production was elevated in ischemic muscle on day 7 after surgery, and bilirubin 
reduced the ischemia-induced superoxide production (Fig. 1E). 
Bilirubin effects on eNOS and Akt phosphorylation and cell activation in HAECs 
To investigate the involvement of bilirubin effect on Akt-eNOS pathway in detail, we 
performed in vitro experiments by using HAECs. Correspondently to the results in 
vivo, bilirubin augmented Akt and eNOS phosphorylation in a time- and dose-
dependent manner (Figure 2A and B).  MTS-based cell proliferation assay showed 
that bilirubin treatment significantly increased cell proliferation (Figure 3A). To test 
the preventive action of bilirubin on cell death, HAECs were treated with bilirubin or 
vehicle and incubated for 48 h in serum- and growth factor- free medium. As shown 
in Figure 2B, bilirubin diminished serum and growth factor starvation-induced cell 
death assessed by an MTS-based assay (Figure 2B). Tube-like formations were also 
pronounced by bilirubin treatment compared to vehicle treatment alone (Figure 3C). 
Moreover, scratch assay demonstrated that bilirubin promoted cell migration in a 
dose-dependent manner (Figure 3D). AMPK as well as Akt are important upstream 
signaling activators of eNOS phosphorylation (25); however, our results showed that 
bilirubin was not involved in AMPK activation (Figure 2A and B). 
Bilirubin exerts eNOS phosphorylation and cell activation through PI3-kinase-Akt-
dependent pathway 
Next, we analyzed whether Akt pathway was involved in bilirubin induced eNOS 
phosphorylation and ECs activation by using LY294002, a PI3-kinase inhibitor. 
Pretreatment with LY294002 significantly suppressed bilirubin-induced eNOS 
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phosphorylation (Figure 4A). Bilirubin effect on serum- and growth factor-starved 
cell death was canceled by LY294002 pretreatment (Figure 4C). Moreover, bilirubin 
induced ECs activation such as cell proliferation, migration, and tube like formation 
were all abolished by LY294002 pretreatment (Figure 4B, D, and E). These results 
suggested that bilirubin action on eNOS phosphorylation and endothelial cells 
activation is involved in PI3-kinase-Akt mediated pathway.  
 
Discussion  
In the present study, bilirubin also increased Akt and eNOS phosphorylation, 
and augmented capillary density and arterioles number in ischemic muscles, leading 
to the enhancement of blood flow recovery in in vivo mouse ischemic hindlimb 
model.  In accordance with in vivo findings, bilirubin also increased eNOS 
phosphorylation, and activated cell proliferation, migration and tube formation in 
HAECs, contributing to the precipitation of angiogenic response.  The mechanism of 
bilirubin on endothelial cells activation is involved in Akt-eNOS-dependent manner.  
In clinical studies, high serum levels of bilirubin are negatively regulates the 
prevalence of various disorders including cardiovascular diseases such (4-10), chronic 
kidney disease (26), type 2 diabetes (27), and its complications such as neuropathy 
(28) and nephropathy (29). Low bilirubin is a potent endogenous anti-oxidant (11), 
and many studies have reported the relationship between bilirubin effects and anti-
oxidant property in various diseases. In experimental studies, the anti-oxidant effect 
of bilirubin and biliverdin (the precursor of bilirubin) protects diabetic nephropathy 
and impaired glucose tolerance through suppressing NADPH oxidase (30, 31).  
Hyperbilirubinemia suppresses angiotensin II-induced hypertension through 
ameliorating endothelium-dependent vasodilation via the reduction of vascular 
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oxidative stress in Gunn rats (32) or mice treated with a drug that competes with 
bilirubin (33). In clinically, oxidative stress is lower in patients with Gilbert syndrome 
(12). Moreover, Dekker et al. have clarified that a bilirubin-increasing drug 
ameliorated plasma anti-oxidant capacity in patients with type 2 diabetes mellitus 
(34).  Therefore, the protective mechanism of bilirubin has been generally considered 
as exerting through the suppression of oxidative stress. In accordance with the above-
mentioned findings, bilirubin treatment reduced the increased oxidative stress in 
ischemic skeletal muscle. Oxidative stress causes endothelial dysfunction and 
impaired revascularization in response to ischemic hindlimb (35, 36). Our previous 
study also showed that deferoxamine, an iron chelator, diminished ischemia-induced 
oxidative stress in adductor muscles through inhibiting Fenton reaction (20).  In 
concordance with our findings, vitamin C, nifedipine, and dipyridamole ameliorate 
ischemia-induced angiogenesis by inhibiting oxidative stress (37-39). Conversely, 
anti-oxidants inhibit eNOS activity (40). We tested the effect of an anti-oxidant, 
tempol, on bilirubin-induced activation of the Akt-eNOS pathway in HAECs, and 
found that tempol did not affect bilirubin-induced Akt and eNOS phosphorylation 
(data not shown). Although further examination is necessary to clarify this issue, the 
anti-oxidant effect of bilirubin could contribute to promote angiogenesis in part. 
There is a close relationship between endothelial function and oxidative stress 
(41). Indeed, patients with Bartter's/Gitelman's syndromes, characterized by normal to 
hypotension, have reduced oxidative stress and higher NO-dependent vasodilatation 
(42). Serum bilirubin is also shown to augment endothelial cells activation indicated 
as coronary flow reserve and flow mediated vasodilatation (7, 12, 19). Bilirubin-
increasing drug also improved endothelium-dependent vasodilation in Type2 diabetic 
patients (34).  The bilirubin effect on endothelium was suggested to exert through the 
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reduction of oxidative stress.  Although the protective effect of bilirubin on various 
organs is also due to anti-oxidant property as mentioned above, bilirubin might have 
additional effects independently to anti-oxidant action.  Bilirubin suppresses vascular 
smooth muscle cells hyperplasia through the inhibitory effect of cell cycle at G1 
phase via the inhibition of p38 mitogen activated protein kinase signaling and 
retinoblastoma tumor suppressor protein in rat (43). Bilirubin also ameliorates insulin 
sensitivity through the inhibitory properties of endoplasmic reticulum stress and 
inflammation (44). Thus, bilirubin might exert its protective action through multiple 
mechanisms in addition to anti-oxidant property.   
In the present study, we demonstrated that bilirubin augmented eNOS and Akt 
phosphorylation, as well as ischemia-induced revascularization, in mice with ischemic 
hindlimb. In in vitro experiments, bilirubin activated endothelial cells function 
through eNOS-dependent pathway, and these bilirubin-induced effect were cancelled 
by PI3-kinase inhibitor, suggesting that direct effects of bilirubin on eNOS activation 
in Akt-dependent signaling.  eNOS is well recognized as a crucial regulator of 
proangiogenic action.  Indeed, it has been shown that eNOS activation leads the 
enhancement of capillaries and arterioles formation in mice with hindlimb ischemia 
(14, 15, 20). Moreover, Akt is an important signaling pathway of eNOS 
phosphorylation (23, 24).  Several studies have shown bilirubin effect on Akt 
activation. Bilirubin treatment enhanced Akt phosphorylation in skeletal muscle of 
high fat diet-induced diabetic mice (44).  Anti-inflammatory action of bilirubin exerts 
IL-10 regulation via Akt-dependent pathway (45). According to our findings, only 
recent article have reported that bilirubin restored endothelial dysfunction through 
ameliorating the reduced Akt-eNOS-NO signaling in aorta of type 2 murine diabetic 
model (46). Our findings strongly suggest that bilirubin promotes angiogenesis 
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through activating endothelial function via Akt-eNOS-dependent axis. Bilirubin 
treatment augmented Akt and eNOS phosphorylation in the ischemic side, as opposed 
to only Akt phosphorylation in the non-ischemic side. Bilirubin augments Akt 
phosphorylation in various tissues and cell types including skeletal muscles (Dong et 
al. Endocrinology 2013). Therefore, bilirubin could increase Akt phosphorylation not 
only in vascular endothelial cells but also in all other tissues including skeletal 
muscles. On the other hand, eNOS is generally expressed only in vascular endothelial 
cells. In the present study, capillaries and arterioles increased in number in the 
ischemic muscles, but not in the non-ischemic muscles with or without bilirubin 
treatment. Therefore, bilirubin-induced an increase in Akt phosphorylation in not only 
vascular endothelial cells but also in all other tissues including muscles, although the 
increase in eNOS phosphorylation in ischemic muscles might be influenced by the 
increase in the number of capillaries and arterioles. Moreover, the detailed mechanism 
of bilirubin action on PI3-kinase-Akt pathway has remained unclear.  Further study is 
necessary for elucidating the upstream mechanism of bilirubin action on this signaling 
pathway. 
In conclusion, bilirubin promotes endothelial cells activation through Akt-
eNOS-dependent pathway, contributing to the enhancement of revascularization in 
murine model with unilateral ischemic hindlimb. This finding indicates a new 
protective effect of bilirubin against insufficient peripheral artery circulation. 
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Figure legends 
Figure 1. Evaluation of revascularization in ischemic hindlimbs of mice with 
bilirubin or vehicle treatment. (A) Left panel: Quantitative analysis of blood flow 
recovery by laser speckle blood flow (LSBF) before surgery and on postoperative 
days 0, 3, 7, 14, and 28. Right panel: Representative LSBF images for hindlimb 
ischemia in vehicle or bilirubin-treated mice. Values are expressed as means ± SEM, 
*P < 0.05, **P < 0.01 vs. mice treated with vehicle, n = 9 in each group. (B) 
Immunohistochemical analysis of capillaries in adductor muscles. Left panel: 
Representative nti-CD31 immunohistochemical staining. Right panel: Quantification 
of capillary density at 28 d after surgery. Values are expressed as means ± SEM, **P 
< 0.01 vs. mice treated with the vehicle, n = 6 in each group. (C) Left panel:  
Representative αSMA immunofluorescence staining. Right panel: Quantification of 
arteriolar numbers in adductor muscles.  Values are expressed as means ± SEM, **P 
< 0.01 vs. mice treated with the vehicle, n = 6 in each group. (D) The phosphorylated 
levels of eNOS and Akt in adductor muscles of mice treated with vehicle or bilirubin. 
Left panel: Representative blots of phospho- and total eNOS, and Akt at 7 d after 
surgery. Right panel: Densitometric analysis of eNOS and Akt phosphorylation. 
Values were expressed as mean ± SEM. *P < 0.05, **P < 0.01, n = 12 in each group. 
(E) Left panel: Representative superoxide detection by dihydroethidium (DHE) 
staining for adductor skeletal muscles from vehicle- or bilirubin-treated mice. Right 
panel: Quantification of DHE fluorescence intensity in skeletal muscles from vehicle- 
or bilirubin-treated mice 7 days after surgery. *P < 0.05, **P < 0.01, n = 5 in each 
group. 
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Figure 2. The effects of Bilirubin on Akt-eNOS pathway in HAECs. (A) Time-
dependent changes in eNOS and phosphorylation in HAECs following bLF 
administration (10 µM). Upper panel: Representative blots of phospho-eNOS, Akt 
and AMPKα, and total eNOS, Akt and AMPKα, and tubulin. Lower panel: 
Densitometric analysis of eNOS, and Akt phosphorylation. The values have been 
expressed in terms of mean ± SEM. **P < 0.01, n = 8 in each group. (B) Dose-
dependent Bilirubin actions on eNOS and Akt phosphorylation at 1 h after bilirubin 
treatment. Left panel: Representative blots of phospho-eNOS and Akt, total eNOS and 
Akt, and tubulin. Right panel: Densitometric analysis of Akt and eNOS 
phosphorylation. Values are expressed in terms of mean ± SEM. *P < 0.05, n = 8 in 
each group. 
Figure 3. Dose effect of 1−100 µM bilirubin on endothelial cells activaiton (A) 
Bilirubin action on endothelial cell proliferation. Cell proliferation was increased by 
bilirubin treatment in a dose-dependent manner. Values are expressed as mean ± SEM. 
*P < 0.05, **P < 0.01, n = 16 in each group. (B) The Effect of bilirubin on serum 
stravation-induced cell death. Cell death was prevented by 10 µM bilirubin. Values 
are expressed in terms of mean ± SEM. **P < 0.01, n = 16 in each group. (C) Left 
panels; Representative figures of tube formation at 18 h after bilirubin stimulation. 
The Effect of bilirubin on tube-like formation. Right panel; Quantitative analysis of  
tube formation. Endothelial cell tube formation was provoked by bilirubin in 10 µM 
concentration. **P < 0.01, n = 6 in each group. (D)  Biliribin effect on cell migration. 
Left panels; Representative pahse contrast images at 0 h and 8 h after scratch.  Right 
panel; Quantitative analysis of  % migrated area. Values are expressed in terms of 
mean ± SEM. *P < 0.05, n = 4 in each group. 
Figure 4. The involvement of PI3-kinase-Akt pathway on bilirubin-induced 
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endothelial cell activation. (A) The induction of eNOS phosphorylation by bilirubin 
was abolished by LY294002. Left panel: Representative blots of phospho-eNOS and 
Akt, and total eNOS, Akt, and tubulin. Right panel: Densitometric analysis of eNOS 
and Akt phosphorylation. The values have been expressed in terms of mean ± SEM. 
**P < 0.01, n = 8 in each group. (B) Bilirubin-induced cell proliferation was 
abolished by LY294002. Values are expressed as mean ± SEM. *P < 0.05, n = 16 in 
each group. (C) The prevntive effct of bilirubin on serum stravation-induced cell 
death was abolished by  LY294002. Values are expressed in terms of mean ± SEM. *P 
< 0.05,**P < 0.01, n = 16 in each group. The augementatio of  (D) tube formation and 
(E) cell migration by bilirubin were inhibited by LY294002. The values have been 
expressed in terms of mean ± SEM. *P < 0.05, **P < 0.01, n = 6–8 in each group.  
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Table.1 Body weight, Blood pressure and pulse rate at day 7 after ischemic hindlimb surgery 
 Post-surgery at day 7 
 Vehicle Bilirubin 
BW (g) 24.3 ± 0.6 24.1 ± 0.4 
Food intake (g/day) 3.5 ± 0.1 3.5 ± 0.1 
Sys. BP (mmHg) 108 ± 1 106 ± 42 
Dia. BP (mmHg) 73 ± 1 72 ± 3 
Pulse rate (beats/min) 664 ± 33 657 ± 20 
 
Values are mean ± SEM. n=6, respectively. 
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Table.2 Changes of plasma bilirubin concentration 
Time after treatment (h) 1 6 24 
Vehicle-treated mice (mg/dl) 0.28 ± 0.03 0.36 ± 0.08 0.36 ± 0.14 
Bilirubin-treated mice (mg/dl) 0.55 ± 0.04** 0.35 ± 0.04 0.39 ± 0.06 
 
**p<0.01 vs vehicle treatment group 
Values are mean ± SEM. n=4-6, respectively. 
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